Get the Stockscreener App
5.79
0.17%
0.010
Pre-market:
5.79
Nevro Corp stock is traded at $5.79, with a volume of 1.12M.
It is up +0.17% in the last 24 hours and up +1.22% over the past month.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
See More
Previous Close:
$5.78
Open:
$5.79
24h Volume:
1.12M
Relative Volume:
1.16
Market Cap:
$219.32M
Revenue:
$425.17M
Net Income/Loss:
$-92.21M
P/E Ratio:
-2.2529
EPS:
-2.57
Net Cash Flow:
$-67.42M
1W Performance:
+0.00%
1M Performance:
+1.22%
6M Performance:
+0.00%
1Y Performance:
-59.62%
1-Day Range:
$5.78
$5.82
1-Week Range:
$5.73
$5.82
52-Week Range:
$3.165
$14.70
Nevro Corp Stock (NVRO) Company Profile
Name
Nevro Corp
Sector
Industry
Phone
650-251-0005
Address
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Compare NVRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
5.79 | 219.32M | 425.17M | -92.21M | -67.42M | -2.57 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Upgrade | Jefferies | Underperform → Hold |
| Feb-07-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-03-24 | Initiated | Wells Fargo | Equal Weight |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-09-24 | Upgrade | Citigroup | Sell → Neutral |
| Aug-08-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Aug-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-07-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-07-24 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Feb-22-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-21-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| May-31-23 | Initiated | RBC Capital Mkts | Outperform |
| May-15-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Jan-17-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Downgrade | Piper Sandler | Neutral → Underweight |
| Dec-20-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Apr-13-22 | Resumed | Truist | Hold |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-09-21 | Downgrade | Truist | Buy → Hold |
| Aug-05-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-05-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-05-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-09-21 | Downgrade | Redburn | Buy → Neutral |
| Jul-06-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-02-21 | Initiated | Piper Sandler | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-08-20 | Upgrade | UBS | Sell → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Mar-20-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-20-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-28-18 | Initiated | UBS | Sell |
| Nov-07-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-06-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-06-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-19-18 | Downgrade | Goldman | Neutral → Sell |
| Jul-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-08-18 | Reiterated | Canaccord Genuity | Buy |
| May-08-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-08-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
View All
Nevro Corp Stock (NVRO) Latest News
StockNews.com Initiates Coverage on Nevro (NYSE:NVRO) - MarketBeat
SEC Form DEFM14A filed by Nevro Corp. - Quantisnow
StockNews.com Begins Coverage on Nevro (NYSE:NVRO) - MarketBeat
Nevro (NYSE:NVRO) Announces Earnings Results - MarketBeat
Nevro Corp. to Host Earnings Call - ACCESS Newswire
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Reduce" by Analysts - MarketBeat
(NVRO) Investment Report - Stock Traders Daily
Nevro Corp. (NYSE:NVRO) Short Interest Update - MarketBeat
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down - Yahoo Finance
Nevro revenue drops 9.1% to USD 105.5M in Q4 2024 - Medical Buyer
Nevro: Q4 Earnings Snapshot - Midland Daily News
Nevro Corp. Reports 2024 Financial Results Amid Acquisition News - TipRanks
Nevro Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results - The Malaysian Reserve
Nevro Corp earnings missed by $0.63, revenue topped estimates - Investing.com Canada
Nevro: Q4 Earnings Snapshot -March 04, 2025 at 04:56 pm EST - Marketscreener.com
Nevro reports Q4 revenue beat, but wider loss than expected By Investing.com - Investing.com South Africa
Nevro reports Q4 revenue beat, but wider loss than expected - Investing.com India
Nevro Corp (NVRO) Q4 2024 Earnings Report Preview: What To Expec - GuruFocus.com
Nevro Corp (NVRO) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Globus Medical to Acquire Nevro in $250 Million Deal - The Healthcare Technology Report.
Nevro (NYSE:NVRO) Now Covered by Analysts at StockNews.com - MarketBeat
Globus Medical to acquire Nevro for $5.85 per share - MSN
Investor Network: Nevro Corp. to Host Earnings Call - ACCESS Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Siyata Mobile Inc. (NasdaqSYTA), Bridge Investment Group Holdings Inc. (NYSEBRDG), Nevro Corp. (NYSE – NVRO), 180 Degree Capital Corp. (Nasdaq - TradingView
The Real Story Behind Globus’s Nevro Deal - https://ryortho.com/
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – NVRO, LGTY, AVTE, PLYA - Morningstar
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, PLYA, NVRO on Behalf of Shareholders - Marketscreener.com
Shareholder Alert: The Ademi Firm investigates whether Nevro Corp. is obtaining a Fair Price for its Public Shareholders - Kilgore News Herald
Nevro (NYSE:NVRO) Now Covered by StockNews.com - MarketBeat
Globus Medical beats Street in Q4, stock dips as analysts question Nevro buy - Mass Device
Earnings call transcript: Globus Medical Q4 2024 earnings beat forecasts, shares dip - Investing.com UK
Globus Medical’s $250 Million Acquisition of Nevro Corp. - Global Legal Chronicle
Globus Medical's SWOT analysis: stock outlook amid acquisition and FDA warning - MSN
Globus Medical Pays 38% Premium for Nevro - https://ryortho.com/
Globus Medical to Acquire Nevro Corp. in Strategic $250 Million Deal - MSN
Nevro Corp Stock (NVRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):